Pheochromocytoma and Prazosin

  1. JOHN P. NICHOLSON, Jr., M.D.;
  2. E. DARRACOTT VAUGHN, Jr., M.D.;
  3. THOMAS G. PICKERING, M.D.;
  4. LAWRENCE M. RESNICK, M.D.;
  5. JOSEPH ARTUSIO, M.D.;
  6. HOLLIS D. KLEINERT, Ph.D.;
  7. JORGE A. LOPEZ-OVERJERO, M.D.; and
  8. JOHN H. LARAGH, M.D.
  1. New York, New York

    Abstract

    Prazosin was used to control the signs and symptoms of excessive alpha-adrenergic activity in four patients with pheochromocytomas. Long-term dosage requirements were predicted by the blood pressure response to a single 1-mg oral dose. However, surgical management of the pheochromocytomas was inadequate with prazosin alone, and intravenous phentolamine was required to suppress the pressor surges generated by the tumor during surgical manipulation and excision.

    Article and Author Information

    • ▸From the Cardiovascular Center, Departments of Surgery, Urology, and Anesthesia, The New York Hospital-Cornell University Medical Center; New York, New York.

    • ▸Requests for reprints should be addressed to: John Perry Nicholson, Jr., M.D.; Cardiovascular Center, Room K-400, The New York Hospital-Cornell University Medical Center, 525 East 68th Street; New York, NY 10021.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med October 1, 1983 vol. 99 no. 4 477-479
    1. » Abstract
    2. Full Text (PDF)
    3. References

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 15, 2009, 151 (12)
    1. Alert me to current issues